Today we announced positive results from the ENCORE long-term Phase 3 trial of AXS-12 in narcolepsy. Please read the full release for more details: #narcolepsy

We are sharing data from across our leading neuroscience pipeline at NEI Congress. Come and meet our team at the posters or at Booths 405, 505, and 897. Learn more about the presentations here: #NEIcongress

We have seven presentations from across our broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2024. Come and meet with us at the conference and learn more about the presentations here: #PsychCongress2024

We’re honored to stand with the global narcolepsy community to show support on World Narcolepsy Day. You can learn more about narcolepsy and #WorldNarcolepsyDay here:

This morning we announced that the FDA acknowledged the resubmission of our New Drug Application (NDA) for AXS-07 for the acute treatment of migraine and set a PDUFA action goal date of January 31, 2025. Read more about the news here:

Come and join a thriving team working to make a meaningful difference in the lives of people affected by hard-to-treat CNS disorders. You can learn about our featured open roles in the video below and see all our open roles here: #hiring

Behavioral symptoms of Alzheimer’s disease, such as agitation, are reported in up to 70% of all patients with Alzheimer’s disease. Learn more about resources available for people with Alzheimer’s and their loved ones here: #AlzheimersAwarenessMonth

Looking to make a difference? Check out these open roles where you can join a team on a mission to improve the lives of people with hard-to-treat CNS disorders. Learn about our featured open roles in the video below and see all our open roles here: #hiring

More than 37 million Americans suffer from migraine disorder making it one of the leading causes of disability amongst neurological disorders in the U.S. Check here to learn more about migraine and available resources: #MigraineAwareness #MHAM2024

Alzheimer’s disease is the most common form of dementia, affecting nearly 7 million people in the United States alone. Learn more about resources available for people with Alzheimer’s and their loved ones here: #AlzheimersAwarenessMonth

We have five presentations, including two featured oral plenary presentations, on solriamfetol at SLEEP 2024. Come and meet us at the conference and check here to learn more about the presentations: #SLEEP2024

Please join us at the American Society of Clinical Psychopharmacology (@ASCPorg) Annual Meeting for multiple data presentations. Learn more about the presentations here: #ASCP2024

This year for Fibromyalgia Awareness Day we are sharing resources to help support the 5 million people affected by fibromyalgia in the United States and to educate others. Learn more about fibromyalgia here: #FibromyalgiaAwarenessDay #Fibromyalgia

Fewer than half of U.S. adults with mental illness received treatment in 2021. Many free online resources and tools are available to provide support for people with mental illness. Learn about mental health and available resources here: #MentalHealthMonth

#MentalHealth conditions are extremely prevalent in the United States, affecting almost half of the population. Axsome is developing novel therapies for some of the hardest to treat mental health conditions. Learn more about our R&D efforts here:

Please join us at the 2024 American Academy of Neurology (AAN) Annual Meeting where we have presentations that highlight our innovative neuroscience portfolio. Learn more about our presentations at AAN here: #AANAM #psychiatry #neurology

Join a rapidly growing team where you can help to advance novel treatments for some of the most challenging CNS disorders. Learn about our featured open roles in the video below and see all our open roles here: #hiring

The first week of April is APHA’s (@PublicHealth) National Public Health Week. This year’s theme is “Protecting, Connecting and Thriving” and is focused on how public health is about more than just health care alone. For more info, visit: #NPHW

We are pleased to announce the initiation of the ENGAGE Phase 3 trial in binge eating disorder, the most common eating disorder. Please read here to learn more: #BingeEating

We are pleased to announce positive topline data from the SYMPHONY Phase 3 trial in narcolepsy. Please read the full release for more details: